Metastatic cancer treatment market is driven by an upsurge in research and development activities, and the rising adoption of biologics and biosimilar for the treatment of cancers. Additionally, patients all over the world are looking forward to progressive cancer therapy drugs to arrest their condition, which in turn is increasing the adoption rate of metastatic cancer treatment. Increase in prevalence of disease globally and high medical needs of patients who have metastatic cancer are the factor expected drives the global metastatic cancer treatment market.

Metastatic Cancer Treatment Market was valued at US$ 57.5 Billion in 2024 and is projected to grow at a CAGR of 7.2% to reach US$ 108.5 Billion by 2034.

The report "Metastatic Cancer Treatment Market, By Products (Branded Medicines and Generic Medicines), By Therapeutic Indication (Breast Cancer, Melanoma, Lung Cancer, Prostate Cancer, Colorectal Cancer, and Others), and Region - Forecast to 2034"

Key Highlights:

• On June 13, 2019, Amgen and Allergan plc announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI for all approved indications of the reference product, Herceptin or the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
• On June 2019, AstraZeneca PLC declared that its Lynparza treatment nearly doubled the life-span of patients with metastatic pancreatic cancer in a phase III trial. The trial tested Lynparza tablets as an initial care treatment for metastatic pancreatic cancer patients, whose disease had not progressed after chemotherapy.

Key Market Insights from the report:          

Metastatic Cancer Treatment Market was valued at US$ 57.5 Billion in 2024 and is projected to grow at a CAGR of 7.2% to reach US$ 108.5 Billion by 2034.The market report has been segmented based on product, therapeutic indication, and region.

• By-products, the metastatic cancer treatment market classified into branded medicines and generic medicines.
• Based on therapeutic indication, the metastatic cancer treatment market classified into six major cancer type’s breast cancer, melanoma, lung cancer, prostate cancer, colorectal cancer, and others.
• By region, North America is expected to dominate the target market, owing to Cancer has a major impact on society in the United States and the growing prevalence of breast cancer in the region.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Metastatic Cancer Treatment Market”, By Products (Branded Medicines And Generic Medicines), and Therapeutic Indication (Breast Cancer, Melanoma, Lung Cancer, Prostate Cancer, Colorectal Cancer, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - forecast till 2034

The prominent player operating in the global metastatic cancer treatment market includes AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Clovis Oncology, and Eli Lilly and Company.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions development company that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business. 

To know more

Contact Us:

Sales

Prophecy Market Insights

 U.S.  1 860 531 2574

RoW: 917775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com